Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome

New England Journal of Medicine

Volumn 337, Issue 2, 1997, Pages 105-114

  Jacobson, Mark A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR;

AIDS RELATED COMPLEX; ANTIVIRAL ACTIVITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG UPTAKE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RETINITIS; REVIEW; TREATMENT PLANNING; VIRUS INHIBITION;

ADMINISTRATION, ORAL; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; CYTOSINE; DRUG IMPLANTS; DRUG THERAPY, COMBINATION; FOSCARNET; GANCICLOVIR; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS;

EID: 0030874410     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199707103370207     Document Type: Review

References (94)

1. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med 1993;329:1922-6.
2. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-7.
3. The Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996;114:23-33.
4. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995;9:471-7.
5. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.
6. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994;112:1531-9.
7. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD, Ganciclovir Implant Study Group. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997;337:83-90.
8. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Intern Med 1997;126:257-63.
9. Lalezari JP, Kemper C, Stagg R, et al. A randomized, controlled study of the safety and efficacy of intravenous cidofovir (CDV, HPMPC) for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. In: Volume 2 of Abstracts of the 11th International Conference on AIDS, Vancouver, B.C., July 7-12, 1996:226. abstract.
10. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial: a randomized, controlled trial. Ann Intern Med 1997;126:264-74.
11. Squires KE, Stempien MJ, Shadman A, Buhles WC. Oral ganciclovir versus intravenous ganciclovir maintenance therapy for cytomegalovirus retinitis in patients with AIDS. In: Abstracts of the First National Conference on Human Retroviruses, Washington, D.C., December 12-16, 1993. Washington, D.C.: American Society for Microbiology, 1993:154. abstract.
12. Lalezari J, Friedberg D, Bisset J, Giordano M, Hardy D, Robinson C. A comparison of the safety and efficacy of 3G, 4.5G and 6G doses of oral ganciclovir versus iv ganciclovir for maintenance treatment of CMV retinitis. In: Volume 2 of Abstracts of the 11th International Conference on AIDS, Vancouver, B.C., July 7-12, 1996:226. abstract.
13. Matheron S, Knospe V, Barton S, et al. 6G vs. 3G Doses of ganciclovir in maintenance treatment of CMV retinitis. In: Volume 1 of Abstracts of the 11th International Conference on AIDS, Vancouver, B.C., July 7-12, 1996:296. abstract.
14. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20. [Erratum, N Engl J Med 1992;326:1172.]
15. Holland GN, Gottlieb MS, Yee RD, Schanker HM, Pettit TH. Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. Am J Ophthalmol 1982;93:393-402.
16. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989;107:75-80.
17. Palestine AG, Rodrigues MM, Macher AM, et al. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology 1984;91: 1092-9.
18. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349: 1443-5.
19. Bloom JN, Palestine AG. The diagnosis of cytomegalovirus retinitis. Ann Intern Med 1988;109:963-9.
20. Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology 1985;92:472-84.
21. Holland GN, Shulcr ID. Progression rates of cytomegalovirus retinopathy in ganciclovir treated and untreated patients. Arch Ophthalmol 1992; 110:1435-42.
22. Holland GN, Tufail A, Jordan MC. Cytomegalovirus diseases. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular infection and immunity. St. Louis: Mosby-Year Book, 1996:1088-129.
23. Crumpacker CS. Ganciclovir. N Engl J Med 1996;335:721-9.
24. Wagstaff AJ, Bryson HM. Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994;48:199-226.
25. Lea AP, Bryson HM. Cidofovir. Drugs 1996;52:225-30.
26. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358:162-4. [Errata, Nature 1992;359:85, 1993;366:756.]
27. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992;358:160-2.
28. Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJ. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 1992;41:197-202.
29. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995;172:239-42.
30. Tatarowicz WA, Lurain NS, Thompson KD. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J Infect Dis 1992;166:904-7.
31. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996;70:1390-5.
32. Cherrington JM, Fuller MF, Lalezari JP, Miner R, Chen MS, Drew WL. In vitro antiviral susceptibilities of isolates from CMV retinitis patients receiving first or second line cidofovir therapy. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22-26, 1997:120. abstract.
33. Drew WL, Miner R, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993;1:179-85.
34. Cherrington JM, Miner R, Hitchcock MJM, Lalezari JP, Drew WL. Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug. J Infect Dis 1996; 173:987-92.
35. Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1995; 17:425-32.
36. DeArmond B. Future directions in the management of cytomegalovirus infections. J Acquir Immune Defic Syndr 1991;4:Suppl 1:s53-s56.
37. Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A 1985;82:2473-7.
38. Jabs DA, Newman C, De Bustros S, Polk BF. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987;94:824-30.
39. Jabs DA, Wingard JR, de Bustros S, de Miranda P, Saral R, Santos GW. BW B759U for cytomegalovirus retinitis: intraocular drug penetration. Arch Ophthalmol 1986;104:1436-7.
40. Henry K, Cantrill H, Fletcher C, Chinnock BJ, Balfour HH Jr. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987;103:17-23.
41. Sanborn G, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch Ophthalmol 1992;110:188-95.
42. Taburet AM, Katlama C, Blanshard C, et al. Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients. Antimicrob Agents Chemother 1992;36:1821-4.
43. Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995;172:951-6.
44. Diaz Llopis M, Espana E, Munoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol 1994;78:120-4.
45. Pearson PA, Jaffe GJ, Ashton P. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol 1993;115:686-8.
46. Cundy KC, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995;39:1247-52.
47. Aduma P, Connelly MC, Srinivas RV, Fridland A. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol Pharmacol 1995;47:816-22.
48. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995;171:788-96.
49. Dunn JP, MacCumber MW, Forman MS, Charache P, Apuzzo L, Jabs DA. Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. Am J Ophthalmol 1995;119:587-96.
50. Jacobson MA, Drew WL, Feinberg J, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis. J Infect Dis 1991;163:1348-51.
51. Jacobson MA, Polsky B, Causey D, et al. Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis. Antimicrob Agents Chemother 1994;38:1190-3.
52. Jacobson MA, O'Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989;33:736-41.
53. Studies of Ocular Complications of AIDS (SOCA), AIDS Clinical Trial Group. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcomes in patients with AIDS and CMV retinitis treated with either foscarnet or ganciclovir. J Infect Dis (in press).
54. Jacobson MA, O'Donnell JJ, Brodie HR, Wofsy C, Mills J. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol 1988;25:339-49.
55. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986;314:801-5.
56. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Ophthalmology 1994;101:1250-61.
57. Jacobson MA, Wulfsohn M, Feinberg JE, et al. Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS 1994;8:451-9.
58. Jabs D. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 1995;93:623-83.
59. Freeman WR, Friedberg DN, Berry C, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am J Ophthalmol 1993;116:713-20.
60. Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy: use of standardized system for the assessment of disease outcome. Arch Ophthalmol 1989;107:1759-66.
61. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991;115:665-73.
62. Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993;168:557-63.
63. Holland GN, Levinson RD, Jacobson MA, AIDS Clinical Trials Group Protocol 915 Team. Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. Am J Ophthalmol 1995;119:576-86.
64. Engstrom RE Jr, Holland GN. Local therapy for cytomegalovirus retmopathy. Am J Ophthalmol 1995;120:376-85.
65. Saran BR, Maguire AM. Retinal toxicity of high dose intravitreal ganciclovir. Retina 1994;14:248-52.
66. Jacobson MA, Causey D, Polsky B, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis 1993;168:444-8.
67. Laskin OL, Cederberg DM, Mills J, Eron LJ, Mildvan D, Spector SA. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med 1987;83:201-7.
68. Jacobson MA, Stanley HD, Heard SE. Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS 1992;6:515-7.
69. Jacobson MA. Review of the toxicities of foscarnet. J Acquir Immune Defic Syndr 1992;5:Suppl 1:S11-S17.
70. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab 1991;72:1130-5.
71. Jacobson MA, de Miranda P, Cederberg DM, et al. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother 1987;31:1251-4.
72. Spector S, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995;171:1431-7.
73. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 1985;152:833-4.
74. Brown F, Arum I, Francis G, Patel M, Malcolm S. Ganciclovir prodrug (RS-79070) - multiple dose, dose-ranging study with effect of food. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22-26, 1997:209. abstract.
75. Grossniklaus HE, Frank KE, Tomsak RL. Cytomegalovirus retinitis and optic neuritis in acquired immune deficiency syndrome. Ophthalmology 1987;94:1601-4.
76. Snoeck R, Sakuma T, De Clercq E, Rosenberg I, Holy A. (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 1988;32:1839-44.
77. Polis MA, Spooner KM, Baird BF, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995;39:882-6.
78. Manischewitz JF, Quinnan GV Jr, Lane HC, Wittek AE. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1990;34:373-5.
79. Freitas VR, Fraser Smith EB, Matthews TR. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res 1989;12:205-12.
80. Cantrill HL, Henry K, Melroe H, Knobloch WH, Ramsay RC, Balfour HH Jr. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir long-term results. Ophthalmology 1989;96:367-74.
81. Ussery FM III, Gibson SR, Conklin RH, Piot DF, Stool EW, Conklin AJ. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1988;95:640-8.
82. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991;98:1348-53.
83. Anand R, Nightingale SD, Fish RH, Smith TJ, Ashton P. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol 1993;111:223-7.
84. Marx JL, Kapusta MA, Patel SS, et al. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch Ophthalmol 1996;114:815-20.
85. Dunkle LM, Petty B, Reynolds L, Hall R, Cross A, Smaldone L. Lobucavir: a promising broad-spectrum antiviral agent. In: Supplement to Abstracts of the 11th International Conference on AIDS, Vancouver, B.C., July 7-12, 1996:20. abstract.
86. Biron KK, Davis MG, Stanat SC, et al. Antiviral activity and mechanism of action of 1263W94, a benzimidazole riboside inhibitor of human cytomegalovirus. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996. Washington, D.C.: American Society for Microbiology, 1996:168. abstract.
87. Wang LH, Yogendran L, Weller S, Sallabank P, Wiggs R, Bye A. A phase I trial evaluating the tolerability and pharmacokinetics (PK) of 1263W94 following single oral administration of escalating doses in normal healthy volunteers. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996. Washington, D.C.: American Society for Microbiology, 1996:168. abstract.
88. Xiong XF, Chen MS. Inhibition of human cytomegalovirus DNA polymerase by PMEA and PMPA diphosphates. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996. Washington, D.C.: American Society for Microbiology, 1996:168. abstract.
89. Hutcherson SL, Palestine AG, Cantrill HL, et al. Antisense oligonucleotide safety for CMV retinitis in AIDS patients. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995. Washington, D.C.: American Society for Microbiology, 1995:204. abstract.
90. Kirsch LS, Arevalo F, De Clercq E, et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995;119:466-76.
91. Rahhal FM, Arevalo JF, Chavez de la Paz E, Munguia D, Azen SP, Freeman WR. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS: a preliminary report. Ann Intern Med 1996; 125:98-103.
92. Tolpin M, Pollard R, Tierney M, Nokta M, Wood D, Hirsch M. Combination therapy of cytomegalovirus retinitis with a human monoclonal anti-CMV antibody (SDZ MSL 109) and either ganciclovir (DHPG) or foscarnet (PFA). In: Abstracts of the Ninth International Conference on AIDS/Fourth STD World Congress, Berlin, Germany, June 6-11, 1993: 54. abstract.
93. Dieterich D. Monoclonal antibody CMV retinitis trial: preliminary results In: Supplement to Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996. Washington, D.C.: American Society for Microbiology, 1996:8. abstract.
94. Snoeck R, Andrei G, Schols D, Balzarini J, De Clercq E. Activity at different antiviral drug combinations against human cytomegalovirus replication in vitro. Eur J Clin Microbiol Infect Dis 1992;11:1144-55.